Nafamostat for severe infection-related blood clotting issues
Part of Infections clinical trials.
This trial tests a medication called nafamostat mesilate to help control blood clotting problems caused by severe infections (sepsis). It may be an option for people with sepsis who are at risk of bleeding but do not have active bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious infection along with signs of organ failure (sepsis).
- You are at least 18 years old and not pregnant or breastfeeding.
- You do not have active bleeding or a high risk of bleeding (like recent trauma, head injury, or a bleeding disorder).
- You have not taken certain blood thinners (like heparin, warfarin, aspirin, or similar drugs) recently.
- You are expected to stay in the ICU for more than 24 hours.
- You do not have a terminal illness that means you are near the end of life.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two blood thinners (nafamostat and heparin) during kidney dialysis for people with sepsis-related acute kidney injury. The goal is to find which is safer and works better.
This trial tests two different blood-thinning methods used during continuous kidney-support treatment (CRRT) for patients who have developed severe kidney injury due to sepsis. The goal is to see which method works better and is safer for patients in this critical condition.
This study tests a new drug (BAY 3389934) for people with sepsis who also have a blood clotting problem. It aims to find the right dose and make sure the drug is safe.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial studies whether combining anisodamine (a medicine for certain gut/smooth-muscle effects) with a low-molecular-weight blood thinner helps treat sepsis. It may be aimed at improving outcomes compared with standard care, but eligibility depends on safety factors like bleeding risk and organ function.
This trial looks at whether a blood-filter treatment (called “AN69ST Verse PS” using a hemofilter) can help children with early, serious sepsis and poor circulation or organ problems. It may help stabilize the body faster, but eligibility is limited to certain sepsis situations and recent timing.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.